loss

Party City Announces Closure: Employees Facing Job Losses as Company Winds Down Operations

3 days ago

Party City, a well-known party supply retailer, has announced its decision to wind down operations, leading to significant layoffs across the company. This shocking revelation comes directly from the CEO, who indicated that the decision was a necessary step in response to ongoing financial struggles faced by the iconic brand.

Lilly's Weight Loss Drug Gains Traction After Novo Nordisk's Clinical Trial Setback

3 days ago

In a significant turn of events, shares of Eli Lilly surged following news that competitor Novo Nordisk faced challenges in its clinical trials for a key weight loss drug. This development highlights a growing advantage for Lilly in the realm of obesity treatments, potentially reshaping the competitive landscape of the pharmaceutical industry.

End of Shortage: FDA Declares Lilly's Weight Loss Drug Readily Available in the U.S.

4 days ago

In a significant development for the U.S. healthcare landscape, the Food and Drug Administration (FDA) has announced that the shortage of Eli Lilly's groundbreaking weight loss medication, semaglutide, has officially come to an end. This news comes as a relief to countless individuals grappling with obesity and seeking effective treatments to support their weight loss journeys.

Merck Secures Groundbreaking Deal for Obesity Drug in China Valued at Nearly $2 Billion

5 days ago

In a significant stride towards addressing the global obesity epidemic, pharmaceutical giant Merck has announced a landmark agreement with Chinese biopharmaceutical company, Eddingpharm. This deal, valued at nearly $2 billion, marks Merck’s strategic entry into the rapidly expanding weight-loss drug market in China. The partnership is expected to leverage the unique characteristics of both companies to improve patient outcomes in one of the world's largest markets for obesity treatment.

Concerns Rise Over Prescribing Weight Loss Drugs to Anorexia Patients

7 days ago

In recent weeks, increasing alarm has arisen surrounding the prescription of weight loss medications, particularly GLP-1 receptor agonists such as Semaglutide and Liraglutide, to individuals grappling with anorexia. Experts are raising red flags over this concerning trend, arguing that these drugs, originally designed for obesity management, could exacerbate the already precarious situation of patients suffering from eating disorders.

HSBC Faces Legal Action from Australian Regulator Over Scam Losses

8 days ago

In a significant turn of events, HSBC Holdings plc has found itself embroiled in a lawsuit initiated by the Australian financial regulator, the Australian Securities and Investments Commission (ASIC). This legal action revolves around the bank’s alleged failures to adequately safeguard customers against scams, leading to substantial financial losses for many individuals.

Ozempic's Connection to Rare Vision Loss Confirmed by Major Study

10 days ago

A groundbreaking new study has established a confirmed link between the diabetes medication Ozempic and an increased risk of rare but severe vision loss. The findings are significant, particularly as Ozempic has gained immense popularity for its use in weight management and diabetes treatment. This revelation comes from a comprehensive trial involving thousands of participants, shedding light on an adverse effect that the medical community has been closely monitoring.

Mass Layoffs Loom at Fintech Lender Stenn Following Collapse

11 days ago

In a shocking turn of events, Stenn, the recently collapsed fintech lender, has confirmed that a majority of its employees will be terminated as the company wraps up its operations. This news comes after Stenn encountered significant financial difficulties, leading to its abrupt downfall amidst shifts in the financial technology landscape.

Eli Lilly Launches Affordable Zepbound Weight Loss Treatment in Major Move

12 days ago

In a groundbreaking decision aimed at expanding access to weight loss medications, pharmaceutical giant Eli Lilly has announced the rollout of its lower-cost version of the prescription drug Zepbound. This strategic move, set to occur in early 2024, underscores the company's commitment to addressing the growing demand for effective weight management solutions amidst soaring obesity rates in the United States and beyond.

The Stark Reality: Insurers Face Climate Losses Nearly Equal to Fossil Fuel Premiums

14 days ago

In a striking report that underscores the mounting risks posed by climate change, recent data indicates that insurance companies are nearing a critical point where their losses from climate-related disasters almost equate to the premiums they collect from the fossil fuel industry. This alarming juxtaposition reveals a significant imbalance in the insurance sector, raising questions about the sustainability of current practices in the face of increasingly severe weather-related events.